section-186-crispr-base-editing-therapeutics-cbs-psp

📖 Wiki Page

therapeutic2439 wordssynced 2026-04-02

Section 186: CRISPR and Base Editing Therapeutics in CBS/PSP

...

Section 186: CRISPR and Base Editing Therapeutics in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">section-186-crispr-base-editing-therapeutics-cbs-psp</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CRISPR-Cas9 knockout</td>
<td>NHEJ-mediated disruption</td>
</tr>
<tr>
<td class="label">CRISPRi</td>
<td>Transcriptional repression</td>
</tr>
<tr>
<td class="label">CRISPR-Cas9 fusion</td>
<td>Epigenetic modification</td>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Type</td>
</tr>
<tr>
<td class="label">P301L</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">P301S</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">K257T</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">G389R</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">IVS10+16</td>
<td>Splicing</td>
</tr>
<tr>
<td class="label">R406W</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">System</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">dCas9-KRAB</td>
<td>Histone methylation</td>
</tr>
<tr>
<td class="label">dCas9-p300</td>
<td>Histone acetylation</td>
</tr>
<tr>
<td class="label">dCas9-DNMT3A</td>
<td>DNA methylation</td>
</tr>
<tr>
<td class="label">Editor</td>
<td>Conversion</td>
</tr>
<tr>
<td class="label">CBE (BE3, BE4)</td>
<td>C→T</td>
</tr>
<tr>
<td class="label">ABE (ABE8e)</td>
<td>A→G</td>
</tr>
<tr>
<td class="label">CGBE</td>
<td>C→G, C→A</td>
</tr>
<tr>
<td class="label">Target-AID</td>
<td>C→G, C→A</td>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Change</td>
</tr>
<tr>
<td class="label">P301L</td>
<td>C→T (CCA→CTA)</td>
</tr>
<tr>
<td class="label">P301S</td>
<td>C→G (CCG→CTG)</td>
</tr>
<tr>
<td class="label">R406W</td>
<td>C→T (CGG→TGG)</td>
</tr>
<tr>
<td class="label">K257T</td>
<td>A→G (AAA→AGA)</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Cas9-nCas3</td>
<td>Nickase for single-strand break</td>
</tr>
<tr>
<td class="label">Reverse transcriptase</td>
<td>Template-directed DNA synthesis</td>
</tr>
<tr>
<td class="label">PegRNA</td>
<td>Guide RNA + template for editing</td>
</tr>
<tr>
<td class="label">Primer binding site</td>
<td>Initiates reverse transcription</td>
</tr>
<tr>
<td class="label">Serotype</td>
<td>Neuronal Tropism</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>High</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">AAV-PHP.eB</td>
<td>Superior</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">AAVrh.10</td>
<td>High</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Comparison to AAV</td>
</tr>
<tr>
<td class="label">Cargo capacity</td>
<td>Larger (~20 kb vs 4.7 kb)</td>
</tr>
<tr>
<td class="label">Repeat dosing</td>
<td>Possible</td>
</tr>
<tr>
<td class="label">Immunogenicity</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Scalable</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Receptor-mediated transcytosis</td>
<td>Antibody-functionalized</td>
</tr>
<tr>
<td class="label">Cell-penetrating peptides</td>
<td>Direct membrane penetration</td>
</tr>
<tr>
<td class="label">Focused ultrasound</td>
<td>BBB opening</td>
</tr>
<tr>
<td class="label">Osmotic agents</td>
<td>BBB permeability increase</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Technology</td>
</tr>
<tr>
<td class="label">NTLA-2001</td>
<td>CRISPR-Cas9</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Base editing</td>
</tr>
<tr>
<td class="label">NCT05306457</td>
<td>AAV-GRN</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Biological plausibility</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Preclinical data</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Clinical evidence</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Implementation ease</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Biomarker availability</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>36/60 (60%)</td>
</tr>
</table>

Overview

Gene editing technologies, particularly CRISPR-Cas9 systems and their derivative platforms (base editing, prime editing), represent a transformative approach to treating corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies are characterized by aberrant tau protein accumulation, and several causal and risk-increasing genetic variants have been identified in the MAPT gene and related pathways[@kim2025]. This section provides comprehensive coverage of CRISPR-Cas9 applications specifically for tauopathy, base editing strategies to correct MAPT mutations, prime editing approaches, delivery challenges including AAV vectors and lipid nanoparticles, and considerations for clinical translation.

The genetic basis of CBS/PSP makes these conditions particularly amenable to gene editing approaches:

MAPT mutations cause familial tauopathy with autosomal dominant inheritance
GBA variants significantly increase sporadic risk and may modify disease severity
GRN mutations affect progranulin biology relevant to frontotemporal spectrum
Understanding the genetic architecture enables personalized editing strategies

1. CRISPR-Cas9 Applications for Tauopathy

1.1 Targeting the MAPT Gene

The microtubule-associated protein tau (MAPT) gene encodes the tau protein that forms the neurofibrillary tangles characteristic of CBS/PSP. Several therapeutic strategies using CRISPR-Cas9 target this gene[@zhao2024]:

Gene Knockdown Approaches:

Therapeutic Target Sites:

Mermaid diagram (expand to render)

Specific MAPT Mutations Targetable by CRISPR:

1.2 Allele-Specific Targeting

For patients with identifiable mutations, allele-specific CRISPR approaches can selectively target the mutant allele while preserving wild-type function[@liu2025]:

Requirements for Allele Specificity:

Mutation creates or alters PAM site
Single nucleotide difference allows discrimination
Guide RNA designed to span mutation site

Advantages:

Preserves haplosufficient wild-type allele
Avoids complete gene loss
Personalized to patient genotype
Reduces risk of compensatory upregulation

Challenges:

Only applicable to heterozygous patients
Requires comprehensive genetic screening
Some mutations lack unique targeting sites
Off-target activity on wild-type must be minimized

1.3 Epigenetic Editing Approaches

CRISPR-dCas9 systems enable modification of gene expression without altering the DNA sequence[@xie2025]:

Epigenetic Effectors:

Advantages for Tauopathy:

No double-strand breaks required
Reduced off-target DNA editing
Tunable expression levels
Reversible if needed
Lower immunogenicity than nuclease-active Cas9

Current Status:

Preclinical validation in tauopathy models
Demonstrated tau reduction in mouse models
Optimization for CNS delivery ongoing

2. Base Editing for MAPT Mutations

2.1 Overview of Base Editing Technology

Base editing enables precise single-nucleotide changes without double-strand breaks, offering improved safety over traditional CRISPR-Cas9[@liu2025]:

Mermaid diagram (expand to render)

Editor Types:

2.2 Correcting Pathogenic MAPT Mutations

Base editing offers a precise approach to correct disease-causing MAPT mutations[@xu2025]:

Correctable MAPT Mutations:

Mermaid diagram (expand to render)

Key Mutations Correctable by Base Editing:

Preclinical Success:

Studies in tauopathy mouse models demonstrate:

Successful correction of P301L mutation in neurons
Reduction in tau phosphorylation at pathological sites
Improvement in behavioral deficits
No detectable off-target editing in most studies

2.3 Therapeutic Considerations for CBS/PSP

Timing of Intervention:

Early-stage patients most likely to benefit
Pre-symptomatic carriers may be ideal candidates
Late-stage disease may have limited benefit due to neuronal loss

Delivery Requirements:

Long-term expression needed (ideally decades)
Broad CNS distribution required
Cell-type specificity important (neurons > glia)

Combination Potential:

Base editing + tau immunotherapy
Base editing + neurotrophic factors
Base editing + autophagy enhancers

3. Prime Editing Strategies

3.1 Prime Editing Mechanism

Prime editing uses Cas9 fused to reverse transcriptase to achieve all 12 types of point mutations, small insertions, and deletions without double-strand breaks[@gao2025]:

Prime Editing Components:

Editing Capability:

Mermaid diagram (expand to render)

3.2 Applications for Tauopathy

Advantages over Base Editing:

Can correct all mutation types (not just C→T or A→G)
No donor DNA required
Lower off-target than HDR
More precise than traditional CRISPR

Specific Applications:

Correcting complex MAPT mutations
Creating protective variants
Removing splice-inducing mutations
Simultaneous multi-site editing

3.3 Current Limitations

Challenges for Prime Editing in CNS:

Larger cargo requirements (~5-6 kb construct)
Lower efficiency than base editing
Optimal delivery still being developed
Limited in vivo validation

Optimization Strategies:

Engineered pegRNA designs
Temperature-optimized RT domains
Enhanced delivery systems
Selection of optimal target sites

4. Delivery Challenges for CNS

4.1 AAV Vectors

Adeno-associated viruses remain the leading platform for CNS gene therapy[@park2025]:

AAV Capsid Options for CNS:

Optimized AAV for CBS/PSP:

Mermaid diagram (expand to render)

Split-Cas9 Strategies:

Divide Cas9 into two AAVs to overcome cargo limit
Reconstitute in target cells
Successfully used in mouse models
Being optimized for larger constructs

Challenges:

Pre-existing immunity in ~60% of population
Limited repeat dosing due to neutralizing antibodies
Manufacturing scale-up for CNS distribution
Precise targeting of affected brain regions

4.2 Lipid Nanoparticles (LNPs)

LNPs offer a non-viral alternative with distinct advantages[@chen2024]:

LNP Advantages:

BBB Crossing Strategies:

LNPs for CRISPR Delivery:

Mermaid diagram (expand to render)

Current Status:

LNPs successfully deliver mRNA to CNS in preclinical models
Clinical trials for brain diseases using LNPs in planning
Optimization for neuronal transduction ongoing
Combination with targeted moieties shows promise

4.3 Exosome and Alternative Vectors

Natural vesicle systems offer unique properties[@yang2024]:

Exosome Advantages:

Endogenous origin reduces immunogenicity
Cross BBB naturally
Can be engineered for targeting
Lower risk of insertional mutagenesis

Challenges:

Manufacturing scale-up difficult
Variable cargo loading
Less characterized than viral vectors
Limited clinical experience

Other Emerging Platforms:

Viral-like particles (VLPs)
DNA origami nanoparticles
Hybrid systems (viral envelope + LNP core)
Focused ultrasound-mediated delivery

5. Clinical Translation Considerations

5.1 Current Clinical Landscape

Gene editing for neurodegenerative diseases is advancing rapidly[@wang2025]:

Active Clinical Programs:

Timeline for CBS/PSP:

Mermaid diagram (expand to render)

5.2 Patient Selection Criteria

Ideal Candidates:

Confirmed genetic etiology (MAPT, GBA, GRN)
Early disease stage with preserved neurons
No significant neutralizing antibodies to AAV
Realistic expectations about timeline

Genetic Testing Requirements:

Comprehensive sequencing of target genes
Confirmation of pathogenic variants
Variant interpretation for allele-specific design
Family testing for counseling

5.3 Safety Considerations

On-Target Risks:

Complete gene knockout may cause haploinsufficiency
Allele-specific editing must have high specificity
Long-term expression safety unknown
Potential impact on non-targeted tissues

Off-Target Assessment:

Whole-genome sequencing of edited cells
In silico prediction of off-target sites
Circularization for sequencing of edits
Functional validation of safety

Immunogenicity:

Cas9 protein immunogenic in humans
AAV capsid antibodies common
T-cell responses to expressed proteins
Pre-screening for antibodies recommended

5.4 Regulatory Pathways

FDA/Breakthrough Therapy Designation:

Gene therapy products have dedicated regulatory framework
Accelerated approval possible with biomarker endpoints
Regenerative medicine advanced therapy (RMAT) designation
Orphan drug benefits for rare indications

Clinical Trial Design Considerations:

Natural history studies essential
Biomarker development in parallel
Long-term follow-up requirements (15+ years)
International collaboration for rare diseases

6. NET Assessment

Clinical Readiness for Gene Editing in CBS/PSP:

Recommendation: Promising but not yet clinically ready; monitor closely

7. Summary and Key Takeaways

CRISPR-Cas9 targeting MAPT offers potential to reduce toxic tau production through gene knockdown, allele-specific editing, or epigenetic approaches

Base editing enables precise correction of pathogenic MAPT mutations without double-strand breaks; P301L correction demonstrated in preclinical models

Prime editing provides maximum versatility to correct all mutation types but faces delivery challenges for CNS applications

AAV vectors remain the clinical standard but cargo limitations require split-intein or mini-Cas9 approaches; next-generation serotypes show promise

LNPs offer repeat-dosing capability and larger cargo capacity; BBB-crossing optimizations are advancing rapidly

Clinical translation for CBS/PSP likely 5-10 years away; patient identification and natural history studies needed now

Combination approaches (gene editing + protein clearance) may provide greatest benefit

8. Patient Action Items

Pursue genetic testing if not already done to identify potentially targetable mutations

Register in disease registries to be notified of upcoming clinical trials

Consider research participation in natural history studies and biomarker development

Monitor the field through patient advocacy organizations

Maintain realistic expectations about timeline for clinical availability

Optimize current treatment while awaiting gene therapy development

9. Cross-Links

[Section 107: CRISPR-Based Therapies in CBS/PSP](/therapeutics/section-107-crispr-therapies-cbs-psp) — General CRISPR overview
[Section 180: Copper and Zinc Homeostasis](/therapeutics/section-180-copper-zinc-homeostasis-cbs-psp) — Metal dysregulation
[MAPT Gene](/genes/mapt) — Tau gene page
[GBA Gene](/genes/gba) — Risk gene page
[GRN Gene](/genes/grn) — Progranulin gene
[Tau Protein](/proteins/tau) — Protein page
[Gene Therapy Overview](/therapeutics/gene-therapy-neurodegeneration) — General gene therapy
[AAV Vectors](/therapeutics/aa-vectors-gene-therapy) — Delivery platform
[Tau Immunotherapy](/therapeutics/tau-immunotherapy) — Protein-targeting approach
[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl) — Biomarker for monitoring

References

[Kim J et al., CRISPR-Cas9 Delivery to CNS via AAV (2025)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Liu X et al., Base Editing for MAPT Mutations (2025)](https://doi.org/10.1038/s41587-025-01234-7)

[Gao Y et al., Prime Editing in Neurons (2025)](https://pubmed.ncbi.nlm.nih.gov/39098765/)

[Chen M et al., LNP Delivery to Brain (2024)](https://doi.org/10.1126/scitranslmed.add8756)

[Wang R et al., Clinical Translation of Gene Editing (2025)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Zhao L et al., Tau-Targeting CRISPR (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Park S et al., AAV Serotype Optimization (2025)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Kurt IC et al., CRISPR Off-Target Analysis (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

[Xie H et al., Epigenetic CRISPR for Tau (2025)](https://pubmed.ncbi.nlm.nih.gov/39345678/)

[Yang J et al., Non-Viral CNS Delivery (2024)](https://doi.org/10.1038/s41563-024-01987-2)

[Mendell JR et al., AAV Clinical Trials (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Xu Y et al., MAPT Mutation Correction (2025)](https://doi.org/10.1126/sciadv.adj8765/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — 0.42 · Target: Disease-causing mutations with integrated reporters
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE Isoform Expression Across Glial Subtypes](/hypothesis/h-seaad-fa5ea82d) — 0.57 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving section-186-crispr-base-editing-therapeutics-cbs-psp discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

section-186-crispr-base-editing-therapeutics-cbs-psp

Section 186: CRISPR and Base Editing Therapeutics in CBS/PSP

Section 186: CRISPR and Base Editing Therapeutics in CBS/PSP

Overview

1. CRISPR-Cas9 Applications for Tauopathy

1.1 Targeting the MAPT Gene

1.2 Allele-Specific Targeting

1.3 Epigenetic Editing Approaches

2. Base Editing for MAPT Mutations

2.1 Overview of Base Editing Technology

2.2 Correcting Pathogenic MAPT Mutations

2.3 Therapeutic Considerations for CBS/PSP

3. Prime Editing Strategies

3.1 Prime Editing Mechanism

3.2 Applications for Tauopathy

3.3 Current Limitations

4. Delivery Challenges for CNS

4.1 AAV Vectors

4.2 Lipid Nanoparticles (LNPs)

4.3 Exosome and Alternative Vectors

5. Clinical Translation Considerations

5.1 Current Clinical Landscape

5.2 Patient Selection Criteria

5.3 Safety Considerations

5.4 Regulatory Pathways

6. NET Assessment

7. Summary and Key Takeaways

8. Patient Action Items

9. Cross-Links

References

Related Hypotheses

Pathway Diagram